Halozyme Therapeutics Prices $1.3 Billion Convertible Notes Offering
Halozyme Therapeutics, Inc. has priced an upsized private offering of $1.3 billion in convertible senior notes due 2033. The notes carry a coupon rate of 1.50%.
San Diego, California – Halozyme Therapeutics, Inc. announced on September 17, 2026, that it has priced an offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033. The size of the offering was increased from its initial target due to demand.
The offering is a private placement to eligible purchasers. Halozyme intends to use the gross proceeds for general corporate purposes, which may include potential acquisitions and working capital needs.
The offering is expected to close on September 20, 2026, subject to customary closing conditions. Halozyme is a biotechnology company focused on drug delivery technologies and holds significant patent portfolios for technologies that enhance drug absorption.
While the company previously indicated potential uses for proceeds, the increased size of the note offering suggests a substantial financing round. Further details on the specific allocation of funds, such as potential debt repurchases, were not immediately elaborated upon.